

# Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic




NEWS PROVIDED BY

**Intezyne, Inc.**

Mar 16, 2018, 08:30 ET

SHARE THIS ARTICLE

TAMPA, Fla., March 16, 2018 /PRNewswire/ -- Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design and validate an assay for use in Intezyne's upcoming Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing anti-cancer therapies.



"In order to optimize further clinical development of our novel Cancer Resistance Pathway (CRP) inhibitor, IT-139, we need a biomarker to stratify patients into potential responders and non-responders," said E. Russell McAllister, CEO. "After evaluating a number of potential partners and technologies, we selected Exosome to design and validate a GRP78 assay using their proprietary exosomal RNA platform technology."

*Image courtesy of National Institutes of Health, U.S. Department of Health and Human Services*

"We are excited to leverage our patented ExoLution isolation kit, a cGMP-grade exosome RNA isolation platform, that provides increased sensitivity to develop a companion diagnostic for IT-139," stated John Boyce, President and CEO for Exosome Diagnostics. "Exploiting a novel mechanism of action, Intezyne's IT-139 has demonstrated remarkable potential to mitigate pancreatic drug resistance. We are thrilled to utilize our leading expertise in the liquid biopsy field, potentially enabling such a promising therapeutic breakthrough."

Intezyne's IT-139 is a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing anti-cancer therapies. IT-139 successfully completed a Phase 1 monotherapy study and was granted an Orphan Drug Designation (ODD) in pancreatic cancer. Additional ODDs are expected in the next 18 months. Intezyne is currently manufacturing IT-139 and expects to initiate one or more combination Phase 1/2 studies by early 2019.

### **About Intezyne, Inc.**

Intezyne is a clinical-stage biopharmaceutical company developing novel anti-cancer therapies that is headquartered at the USF Tampa Bay Technology Incubator. Intezyne currently has two clinical-stage programs: IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing anti-cancer therapies, and IT-141, a novel topoisomerase I (TOP-I) inhibitor for the treatment of colorectal, gastric and other cancers.

For more information, please visit the Company's website at [www.intezyne.com](http://www.intezyne.com).

### **About Exosome Diagnostics, Inc.**

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives.

Visit [www.exosomedx.com](http://www.exosomedx.com) to learn more.

Contact:

E. Russell McAllister, CEO  
[191944@email4pr.com](mailto:191944@email4pr.com), (813) 609-5017

SOURCE

Intezyne, Inc.

Related Links

<http://intezyne.com>